Aldagen Announces Participation in Breakout Sessions at 2009 BIO International Convention

* Reuters is not responsible for the content in this press release.

Mon May 18, 2009 9:14am EDT 

  DURHAM, NC, May 18 (MARKET WIRE) -- 
Aldagen, Inc. today announced that it will be participating in two
Breakout Sessions during the 2009 BIO International Convention taking
place in Atlanta.

    On Tuesday, May 19 at 2:00 pm, Andrew E. Balber, Ph.D., Chief Scientific
Officer of Aldagen, will be participating in a panel titled: "Stem Cells:
Translating Exciting Preclinical Data into Human Clinical Trials." In
addition to Dr. Balber, this session will include a clinician, a
researcher, and a representative from the FDA who will discuss the
challenges of translating preclinical stem cell data into clinical
studies, and the progress that has been made to date.

    On Wednesday, May 20 at 10:00 am, Tom Amick, Chairman and Chief Executive
Officer of Aldagen, will be participating in a panel titled: "'Where's the
Door? I Want to Get Out!' Searching for the Exits." This session will
provide a discussion on financing and exit opportunities for biotech
companies in the current economic climate.

    About Aldagen, Inc.

    Aldagen is a biopharmaceutical company developing proprietary regenerative
cell therapies that target significant unmet medical needs. The company
has four product candidates in clinical trials. Aldagen's most advanced
product candidate, ALD-101, is currently in a pivotal Phase 3 clinical
trial to evaluate its efficacy in improving umbilical cord blood
transplants used to treat inherited metabolic diseases in pediatric
patients. The company also is conducting or supporting Phase 1 or Phase
1/2 clinical trials of three other product candidates: ALD 151 to improve
umbilical cord blood transplants used in the treatment of leukemia,
ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic
heart failure. Aldagen's product candidates consist of specific
populations of adult stem cells that the company isolates using its
proprietary technology.

    

For more information, contact:
Ed Field
President and COO
Aldagen
919-484-2571
Email Contact

Michelle Linn
Linnden Communications
508-362-3087
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.